NDLI: Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study

Content Provider	Springer Nature : BioMed Central
Author	Flendrie, Marcel Vissers, Wynand HPM Creemers, Marjonne CW de Jong, Elke MGJ van de Kerkhof, Peter CM van Riel, Piet LCM
Abstract	Various dermatological conditions have been reported during tumor necrosis factor (TNF)-α-blocking therapy, but until now no prospective studies have been focused on this aspect. The present study was set up to investigate the number and nature of clinically important dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis (RA). RA patients starting on TNF-α-blocking therapy were prospectively followed up. The numbers and natures of dermatological events giving rise to a dermatological consultation were recorded. The patients with a dermatological event were compared with a group of prospectively followed up RA control patients, naive to TNF-α-blocking therapy and matched for follow-up period. 289 RA patients started TNF-α-blocking therapy. 128 dermatological events were recorded in 72 patients (25%) during 911 patient-years of follow-up. TNF-α-blocking therapy was stopped in 19 (26%) of these 72 patients because of the dermatological event. More of the RA patients given TNF-α-blocking therapy (25%) than of the anti-TNF-α-naive patients (13%) visited a dermatologist during follow-up (P < 0.0005). Events were recorded more often during active treatment (0.16 events per patient-year) than during the period of withdrawal of TNF-α-blocking therapy (0.09 events per patient-year, P < 0.0005). The events recorded most frequently were skin infections (n = 33), eczema (n = 20), and drug-related eruptions (n = 15). Other events with a possible relation to TNF-α-blocking therapy included vasculitis, psoriasis, drug-induced systemic lupus erythematosus, dermatomyositis, and a lymphomatoid-papulosis-like eruption. This study is the first large prospective study focusing on dermatological conditions during TNF-α-blocking therapy. It shows that dermatological conditions are a significant and clinically important problem in RA patients receiving TNF-α-blocking therapy.
Related Links	https://arthritis-research.biomedcentral.com/counter/pdf/10.1186/ar1724.pdf
Ending Page	11
Page Count	11
Starting Page	1
File Format	HTM / HTML
ISSN	14786362
DOI	10.1186/ar1724
Journal	Arthritis Research & Therapy
Issue Number	3
Volume Number	7
Language	English
Publisher	BioMed Central
Publisher Date	2005-04-04
Access Restriction	Open
Subject Keyword	Rheumatology Orthopedics Infliximab Rheumatoid Arthritis Patient Etanercept Juvenile Idiopathic Arthritis Adalimumab
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology Rheumatology
Journal Impact Factor	4.4/2023
5-Year Journal Impact Factor	4.9/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Adverse events during anti-TNF therapy in 269 patients with juvenile idiopathic arthritis

Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study

Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

Treatment prescribing patterns in a cohort of patients with juvenile idiopathic arthritis (JIA). Data from the childhood arthritis prospective study (CAPS)

TNF and anti-TNF agents in Behçet's disease

Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study

Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study

Tumour necrosis factor-α levels are elevated in adolescent patients with juvenile idiopathic arthritis on etanercept therapy

Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study

Similar Documents

Adverse events during anti-TNF therapy in 269 patients with juvenile idiopathic arthritis

Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study

Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

Treatment prescribing patterns in a cohort of patients with juvenile idiopathic arthritis (JIA). Data from the childhood arthritis prospective study (CAPS)

TNF and anti-TNF agents in Behçet's disease

Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study

Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study

Tumour necrosis factor-α levels are elevated in adolescent patients with juvenile idiopathic arthritis on etanercept therapy

Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study